Haemonetics (HAE) Revises Annual Guidance Downward

The medical-device company Haemonetics (HAE) revised its annual guidance on February 5, 2026,下调 revenue and EPS expectations. The firm now projects 2026 revenue of $1.35 billion, down from $1.45 billion, and EPS of $1.05, down from $1.15. Management cited softer demand in the U.S. and international markets, supply chain disruptions, and higher input costs as key factors. The revision reflects broader macroeconomic pressures and comes amid ongoing global healthcare spending constraints.